BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer

REFERENCES

• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934.
   PubMed Web of Science ®Google Scholar
• Ortutay C, Nore BF, Vihinen M, Smith CI. Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. Adv Genet. 2008;64:51–80.
   PubMedGoogle Scholar
• Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548–5557.
   PubMed Web of Science ®Google Scholar
• Mano H. Tec family of protein–tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 1999;10(3–4):267–280.
   PubMed Web of Science ®Google Scholar
• Felices M, Falk M, Kosaka Y, Berg LJ. Tec kinases in T cell and mast cell signaling. Adv Immunol. 2007;93:145–184.
   PubMed Web of Science ®Google Scholar
• Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol. 2009;29(4):317–333.
   PubMed Web of Science ®Google Scholar
• Chamorro M, Czar MJ, Debnath J, Requirements for activation and RAFT localization of the T-lymphocyte kinase Rlk/Txk. BMC Immunol. 2001;2:3.
   Google Scholar
• Debnath J, Chamorro M, Czar MJ, rlk/TXK encodes two forms of a novel cysteine string tyrosine kinase activated by Src family kinases. Mol Cell Biol. 1999;19(2):1498–1507.
   PubMedGoogle Scholar
• Weil D, Power MA, Smith SI, Li CL. Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage. Blood. 1997;90(11):4332–4340.
   Google Scholar
• Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A. BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol. 1996;94(3):455–460.
   Google Scholar
• Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997;96(6):1729–1732.
   Google Scholar
• Guo L, Guo Y, Xiao S. Expression of Etk/Bmx tyrosine kinase in intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97(5):428–432.
   Google Scholar
• Guo L, Guo Y, Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology. 2007;72(5–6):410–416.
   Google Scholar
• Dai B, Kim O, Xie Y, Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 2006;66(16):8058–8064.
   PubMed Web of Science ®Google Scholar
• Bagheri-Yarmand R, Mandal M, Taludker AH, Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem. 2001;276(31):29403–29409.
   Google Scholar
• Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci U S A. 1996;93(12):5958–5962.
   Google Scholar
• Tomlinson MG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB. Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk. J Biol Chem. 1999;274(19):13577–13585.
   Google Scholar
• Ellmeier W, Jung S, Sunshine MJ, Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med. 2000;192(11):1611–1624.
   PubMed Web of Science ®Google Scholar
• Tamagnone L, Lahtinen I, Mustonen T, BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene. 1994;9(12):3683–3688.
   Google Scholar
• Valiaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006;27(12):1209–1217.
   PubMedGoogle Scholar
• Rajantie I, Ekman N, Iljin K, Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001;21(14):4647–4655.
   PubMedGoogle Scholar
• He Y, Luo Y, Tang S, Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J Clin Invest. 2006;116(9):2344–2355.
   Google Scholar
• Zhang R, Xu Y, Ekman N, Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem. 2003;278(51):51267–51276.
   PubMed Web of Science ®Google Scholar
• Chen KY, Wu CC, Chang CF, Suppression of Etk/Bmx Protects against ischemic brain injury. Cell Transplant. 2011.
   Google Scholar
• Mitchell-Jordan SA, Holopainen T, Ren S, Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy. Circ Res. 2008;103(12):1359–1362.
   Google Scholar
• Bry M, Kivela R, Holopainen T, Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122(17):1725–1733.
   PubMed Web of Science ®Google Scholar
• Semaan N, Alsaleh G, Gottenberg JE, Wachsmann D, Sibilia J. Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways. J Immunol. 2008;180(5):3485–3491.
   Google Scholar
• Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM. Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2008;370(4):599–602.
   Google Scholar
• Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood. 2008;111(4):1781–1788.
   Google Scholar
• Huesken D, Lange J, Mickanin C, Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol. 2005;23(8):995–1001.
   PubMed Web of Science ®Google Scholar
• Mukherji M, Bell R, Supekova L, Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci U S A. 2006;103(40):14819–14824.
   PubMed Web of Science ®Google Scholar
• Rines DR, Gomez-Ferreria MA, Zhou Y, Whole genome functional analysis identifies novel components required for mitotic spindle integrity in human cells. Genome Biol. 2008;9(2):R44.
   Web of Science ®Google Scholar
• Gottar-Guillier M, Dodeller F, Huesken D, The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. J Immunol. 2011;186(10): 6014–6023.
   Google Scholar
• Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87(5):811–822.
   PubMed Web of Science ®Google Scholar
• Ji H, Pettit A, Ohmura K, Critical roles for interleukin 1 and tumor necrosis factor at in antibody-induced arthritis. J Exp Med. 2002;196(1):77–85.
   PubMed Web of Science ®Google Scholar
• Monach PA, Mathis D, Benoist C. The K/BxN arthritis model. Curr Protoc Immunol. 2008;Chapter 15:Unit.
   Google Scholar
• Dumonde DC, Glynn LE. The production of arthritis in rabbits by an immunological reaction to fibrin. Br J Exp Pathol. 1962;43:373–383.
   PubMed Web of Science ®Google Scholar
• Lens JW, van den Berg WB, van de Putte LB. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: studies on the characteristics of and mechanisms involved in the reaction. Clin Exp Immunol. 1984;55(2):287–294.
   Google Scholar
• Chen KY, Huang LM, Kung HJ, Ann DK, Shih HM. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene. 2004;23(10):1854–1862.
   Google Scholar
• Guo L, Guo Y, Xiao S. Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2. Cancer Lett. 2006;232(2):255–261.
   Google Scholar
• Guo S, Sun F, Guo Z, Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One. 2011;6(3):e17778.
   Google Scholar
• Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther. 2005;4(11):1801–1809.
   Google Scholar
• Guryanova OA, Wu Q, Cheng L, Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011;19(4):498–511.
   Google Scholar
• Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells. 2009;28(1):7–12.
   PubMedGoogle Scholar
• Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670–1673.
   PubMed Web of Science ®Google Scholar
• de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 2009;9(5):580–590.
   PubMed Web of Science ®Google Scholar
• Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood. 1997;90(11):4341–4353.
   Google Scholar
• Tsai YT, Su YH, Fang SS, Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol. 2000;20(6):2043–2054.
   PubMedGoogle Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des. 2009;15(17):1949–1955.
   PubMed Web of Science ®Google Scholar
• Middendorp S, Dingjan GM, Maas A, Dahlenborg K, Hendriks RW. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol. 2003;171(11):5988–5996.
   PubMed Web of Science ®Google Scholar
• Muckelbauer J, Sack JS, Ahmed N, X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase. Chem Biol Drug Des. 2011;78(5):739–748.
   PubMed Web of Science ®Google Scholar
• Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem. 2007;50(3):409–424.
   PubMed Web of Science ®Google Scholar
• Di Paolo JA, Huang T, Balazs M, Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41–50.
   PubMed Web of Science ®Google Scholar
• Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14(4):475–480.
   PubMed Web of Science ®Google Scholar
• Hur W, Velentza A, Kim S, Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 2008;18(22):5916–5919.
   Google Scholar
• Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10(4):307–317.
   PubMed Web of Science ®Google Scholar
• Fowler N, Sharman JP, Smith SM, The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. ASH Annual Meeting Abstracts 2010;116(21):964.
   Google Scholar
• Staudt LM, Dunleavy K, Buggy JJ, The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. ASH Annual Meeting Abstracts 2011;118(21):2716.
   Google Scholar
• Wang L, Martin P, Blum KA, The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. ASH Annual Meeting Abstracts 2011;118(21):442.
   Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107(29):13075–13080.
   PubMed Web of Science ®Google Scholar
• Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med Chem. 2010;2(6):949–964.
   PubMed Web of Science ®Google Scholar